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Abstract
Objectives: Vietnam has significantly scaled up its national antiretroviral therapy (ART) program since 2005. With the aim of
improving Vietnam’s national ART program, we conducted an outcome evaluation of the first five years of the program in
this concentrated HIV epidemic where the majority of persons enrolled in HIV care and treatment services are people who
inject drugs (PWID). The results of this evaluation may have relevance for other national ART programs with significant PWID
populations.
Design: Retrospective cohort analysis of patients at 30 clinics randomly selected with probability proportional to size
among 120 clinics with at least 50 patients on ART.
Methods: Charts of patients whose ART initiation was at least 6 months prior to the study date were abstracted. Depending
on clinic size, either all charts or a random sample of 300 charts were selected. Analyses were limited to treatment-naı̈ve
patients. Multiple imputations were used for missing data.
Results: Of 7,587 patient charts sampled, 6,875 were those of treatment-naı̈ve patients (74.4% male, 95% confidence
interval [CI]: 72.4–76.5, median age 30, interquartile range [IQR]: 26–34, 62.0% reported a history of intravenous drug use, CI:
58.6–65.3). Median baseline CD4 cell count was 78 cells/mm3 (IQR: 30–162) and 30.4% (CI: 25.8–35.1) of patients were at
WHO stage IV. The majority of patients started d4T/3TC/NVP (74.3%) or d4T/3TC/EFV (18.6%). Retention rates after 6, 12, 24,
and 36 months were 88.4% (CI: 86.8–89.9), 84.0% (CI: 81.8–86.0), 78.8% (CI: 75.7–81.6), and 74.6% (CI: 69.6–79.0). Median CD4
cell count gains after 6, 12, 24, and 36 months were 94 (IQR: 45–153), 142 (IQR: 78–217), 213 (IQR: 120–329), and 254 (IQR:
135–391) cells/mm3. Patients who were PWID showed significantly poorer retention.
Conclusions: The study showed good retention and immunological response to ART among a predominantly PWID group
of patients despite advanced HIV infections at baseline.
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Introduction
Vietnam has a population of more than 84 million and an
estimated 2011 adult (15–49 years) HIV prevalence of 0.45% [1].
However, the epidemic is primarily concentrated in most-at-risk
populations, including people who inject drugs (PWID), commer-
cial sex workers (CSW), and men who have sex with men (MSM).
There were an estimated 248,500 people living with HIV/AIDS
in Vietnam in 2011. Among PWID the HIV prevalence was
25.5%; among CSW, 6.8%; and among high-risk MSM, 11.2%
[2]. National size estimates of those high-risk populations were as
high as 336,000 for PWID, 101,000 for CSW, and 393,000 for
MSM [2].
In 2005, in response to the epidemic, the Ministry of Health
(MOH) established the Vietnam Administration for HIV/AIDS
Control (VAAC) to coordinate HIV response activities. The MOH
developed guidelines for diagnosis and treatment of HIV/AIDS
and established outpatient clinics (OPC) where HIV-infected
patients have been offered free care and treatment services.
Nationwide scale-up of a free antiretroviral therapy (ART)
program began in 2005 through a network of HIV outpatient
clinics (OPCs) using a CD4 T-cell count threshold for ART
initiation of 200 cells/mm3. As of December 2011, 57,600 patients
were receiving ART in 305 adult OPCs. This accounted for 53%
of those estimated to be in need of treatment [1]. ART services
have been funded by three major sources: (1) the U.S. President’s
Emergency Plan for AIDS Relief (PEPFAR), (2) the Global Fund
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for AIDS, Tuberculosis and Malaria (GF), and (3) the National
Target Program for HIV/AIDS Prevention and Control (NP).
With the national ART program still in the process of scale-up,
it is important to evaluate the ART program outcomes so that
program weaknesses can be addressed. The goal of this evaluation
was to assess the clinical and programmatic outcomes of adult
HIV-infected patients after ART initiation and factors associated
with those outcomes.
Methods
Vietnam ART Program and Guidelines
The current 2009 Vietnam MOH’s Guidelines for Diagnosis and
Treatment of HIV/AIDS and National ART Protocol state that all HIV-
infected persons who are at least 16 years of age are eligible for
care and treatment services at adult OPCs. Patients are referred
from voluntary counseling and testing sites, hospitals, general
medicine clinics, or peer outreach groups. Once registered for
HIV care services, patients are followed every three to six months
with clinical exams and laboratory testing until eligible for
treatment. In 2009, criteria for starting ART were WHO stage I
or II with CD4 cell count less than 250 cells/mm3, WHO stage III
with CD4 cell count less than 350 cells/mm3, or WHO stage IV
regardless of CD4 cell count [3]. The CD4 threshold for starting
ART among patients with WHO stage I or II was increased to 350
cells/mm3 in 2011. According to the national guidelines in 2009,
MOH-preferred first-line regimens included combinations of
zidovudine (AZT) or stavudine (d4T), lamivudine (3TC), and
nevirapine (NVP) or efavirenz (EFV). However, stavudine was
phased out in 2011 and the combination of tenofovir, lamivudine,
and efavirenz was recommended as the preferred first line
regimen.
OPCs are located at three levels of the health care system:
central, provincial and district levels. A single treatment protocol is
applied at all levels. All clinical data are recorded in the MOH’s
standardized paper-based forms and patient charts. Before ART
initiation, all patients undergo a medical examination, which
includes complete medical history, physical examination, chest
radiograph, complete blood count (CBC), liver transaminases,
hepatitis B surface antigen and hepatitis C antibody testing. CD4
cell count testing is available to patients in most clinics, but HIV
viral load testing is not routinely available. Adherence counseling
sessions are provided to familiarize patients with regimens and
adverse events and to promote adherence. After starting ART,
patients are required to return weekly during the first four weeks to
pick-up their medications, then every two weeks for the next
month, and monthly thereafter. At each visit weight, WHO stage,
and clinical signs and symptoms are recorded. Routine testing for
CBC, liver transaminases and CD4 cell count is performed at 6-
month intervals from ART initiation or before switching to
second-line therapy. Co-trimoxazole prophylaxis is recommended
to patients in WHO stage III or IV regardless of CD4 cell count or
patients in WHO stage I or II with CD4 cell count less than 200
cells/mm3. During the clinical course of care and treatment,
patients are generally offered a variety of HIV services, including
prevention of mother-to-child transmission, TB/HIV screening
and treatment, peer outreach, and needle and syringe programs.
Services for PWID
Because the majority of HIV infections occur among PWID,
services for PWID are a priority of the VAAC. Needle and syringe
programs are available in 35 of 64 provinces. Methadone
maintenance therapy (MMT), which started in 2008 in 2 pilot
provinces, expanded to 41 clinics in 11 provinces by the end of
2011 with more than 7,000 PWID receiving MMT treatment.
However, since the MMT program was in pilot status at the time
of this study, data on ART patients on MMT were limited. Other
programs such as the 100% Condom Use Program, voluntary
counseling and testing, and outreach programs are also generally
available.
Design
This study was a retrospective cohort analysis of adult patients
who started ART at OPCs in Vietnam. Data were abstracted from
patient charts.
Patient Eligibility
All adults 16 years of age or older at the time of ART initiation
who started ART at least 6 months prior to the date of chart
abstraction were eligible for inclusion in the evaluation. Analyses
were limited to ART-naı̈ve patients, defined as patients who
reported no antiretroviral use before ART initiation at participat-
ing clinics.
Sample Size
A sample size of 1,537 was calculated as needed to estimate the
proportion of adults who are alive and on therapy 12 months after
ART initiation, expecting a proportion of approximately 80%,
using a finite population of 28,000, which was the total number of
patients on ART in the country at the time of the study protocol
development, so that a 95% confidence interval equal to the
sample proportion 62% is produced.
Site and Sample Selection
All OPCs providing ART for at least 1 year and with 50 or
more adults on ART as of March 2009 were eligible for
inclusion in the sampling frame. Of the 173 adult ART clinics
active in Vietnam at the time, 120 (69%) met the eligibility
criteria. These 120 clinics included 39 supported by the U.S.
President’s Emergency Plan for AIDS Relief (PEPFAR) (33%),
50 supported by the Global Fund (GF) (42%), and 31 by the
National Program (NP) (25%) providing ART to a total of
25,000 patients (89% of all ART patients countrywide). The 39
PEPFAR-funded clinics accounted for 15,500 (62%) of the
patients, while GF-funded clinics accounted for 6,000 (24%)
patients. Due to funding and staff-time limitations, we randomly
selected 30 (25%) of the 120 eligible OPCs. A multi-stage
sampling strategy was applied: In the first stage, we randomly
selected 12 of 39 PEPFAR-funded clinics, 10 of 50 GF-funded
clinics and 8 of 31 NP-funded clinics using probability pro-
portional to size (PPS). We sampled clinics according to funding
partner because in the early phase of the national ART
program there were differences between partners regarding
clinic location and types (e.g., clinics supported by PEPFAR
were usually at the provincial level or in large cities), and level
of technical support (clinical and lab support were generally
more available to PEPFAR and GF supported clinics); however,
in recent years those differences have become less significant as
a result of increased coordination of services by VAAC. This
approach helped improve the national estimates and allowed for
partner-specific estimates which were useful for feedback related
to partner-specific program implementation. However, it was
not our intention to compare the differences between partners.
In the second stage of the evaluation, for clinics with more than
300 eligible ART patients, we randomly selected a sample of
300 patients from a clinic registry of all patients who ever
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started ART, and for clinics with fewer than 300 eligible ART
patients we selected all patients from that clinic.
Data Collection
Chart abstractions were conducted at the 30 selected clinics.
Re-abstraction and validation was performed on 10% of the
randomly re-selected charts. No personal identifying information
was collected. The data were anonymous and unlinked. All data
were double-entered into an Epi-Info database (Epi Info v.3.3.2
for Windows). SAS 9.2 (SAS Institute Inc., Cary, NC) was used for
comparison and resolution of double-entered data.
Ethical Review
Due to the nature of the evaluation, a waiver of informed
consent for medical record abstraction was requested. The survey
instrument, including the waiver of informed consent, was
approved by the Vietnam Ministry of Health and the Institutional
Review Board of U.S. Centers for Disease Control and Prevention
(Atlanta, Georgia).
Statistical Analysis
All analyses were performed using SAS 9.2 (SAS Institute Inc.,
Cary, NC) and Stata/IC 10.1 (StataCorp, 2009, Stata Statistical
Software: Release 10.1, College Station, TX). Statistical analyses
were weighted and accounted for the complex design of the
evaluation. Domain analyses were performed to appropriately
account for the analysis of subpopulations.
Missing data were assumed missing at random (MAR) [4] and
were imputed multiply via chained equations using the ice
[5,6,7] procedure in Stata. Twenty imputed datasets were
created and estimates were combined according to Rubin’s rules
[4] using the mim procedure [8]. The imputation model
included the Nelson-Aelen estimate of cumulative hazard [9],
baseline demographic and clinical variables, and the event
indicator. Time-to-event data were complete for all individuals.
Twenty-five patients were lost to follow-up (LTFU) after their
first clinic visit and were assigned one day of person-time.
Stratified Kaplan-Meier curves were used to graphically assess
retention proportions. These analyses were limited to the first
imputed dataset. Cox proportional hazards models were used to
identify factors (year of ART initiation, sex, intravenous drug
use, baseline CD4 cell count, baseline WHO stage, baseline
body mass index (BMI), treatment for active tuberculosis disease
(TB), baseline hemoglobin, initial ART regimen, clinic type,
clinic location, clinic size) associated with attrition. Attrition was
defined as discontinuation of ART due to death, loss to follow-
up, or discontinuation of ART medications while remaining in
care. Hazard ratios (HRs), 95% confidence intervals (CI) and p-
values were calculated. Deaths were recorded if documented in
the patient record. Patients who had not presented to the clinic
for more than 90 days since their last recorded visit were
considered lost to follow up. For this study, retention referred to
patients known to be alive and receiving highly active ART at
the end of the follow-up period. For time-to-event analyses,
patients who transferred to another clinic were censored at the
date of transfer. However, for estimating retention proportions
at 6, 12, 24, 36, and 48 months, transfers were excluded from
the retention analysis. Baseline CD4 cell count was defined as
the value on the date closest to ART start date, but not more
than 182 days prior to that date or more than 1 day after that
date. For clinical stages, weight and CD4 cell count at 6
months, 12 months, and 24 months of follow-up were selected;
when multiple values were available the values obtained on the
dates closest to 182 days, 365 days, and 730 days were selected.
Results
Characteristics at Clinic Registration
From March 2010 to May 2010, data from records of 7,587
eligible patients at 30 clinics were abstracted; preliminary results of
the full cohort were presented elsewhere [10]. However, we
focused the analyses on treatment-naı̈ve patients (N = 6,875). All
patients, except one, received ART between 2005 and 2009. At
registration, the majority of patients were in WHO stage III or IV
(69.7%, 95% CI: 64.4–75.1) and had a median CD4 cell count of
73 cells/mm3 (IQR: 28–128). Median CD4 cell count at
registration for patients who started ART was 39 cells/mm3 in
2005, 51 cells/mm3 in 2006, 66 cells/mm3 in 2007, 75 cells/mm3
in 2008, and 87 cells/mm3 in 2009. Median waiting time from
registration to start of ART was 60 days (IQR: 28–149) with
a reduction from 137 days in 2005 to 56 days in 2009.
Characteristics at ART Initiation
Table S1 illustrates the clinical and laboratory characteristics of
patients at ART initiation. Both original and imputed results are
presented. The following text reports weighted imputed data.
The majority of patients were male (74.4%, 95% CI: 72.4–
76.5), median age was 30 years (IQR: 26–34), and 62.0% (95%
CI: 58.6–65.3) reported a history of intravenous drug use (IDU).
Active TB was relatively common at ART initiation (13.9%,
95% CI: 10.4–17.3). Mean BMI was 18.5 (95% CI: 17.1–20.1).
Most patients started ART in the setting of late presentation of
HIV infection. WHO stage III and IV was recorded in 46.9%
(95% CI: 42.6–51.1) and 30.4% (95% CI: 25.8–35.1) of patients,
respectively, and median CD4 cell count was 78 cells/mm3 (IQR:
30–162). Only 15.9% (95% CI: 13.3–18.5) of patients had CD4
cell count $200 cells/mm3 at ART initiation.
Median hemoglobin was 121 g/l (IQR: 105–136) and was
lower among women than men. Grade 4 anemia (hemoglobin
,65 g/l) was seen in 1.9% (95% CI: 1.1–2.6) of patients.
Prevalence of hepatitis B infection was 14.2% (95% CI: 11.9–
16.4); prevalence of hepatitis C infection was 39.6% (95% CI:
34.8–44.3). However, data on hepatitis testing was missing for
many patients (51.4% for hepatitis B and 65.4% for hepatitis C).
Most patients started d4T/3TC/NVP (74.3%, 95%CI: 68.9–79.7)
or d4T/3TC/EFV (18.6%, 95%CI: 14.5–22.7).
Table S1 illustrates the baseline characteristics between patients
who reported injecting drug use (IDU) and patients who did not
report IDU. PWID tended to present with lower CD4 cell count
(69 vs. 96 cells/mm3), more severe WHO stages (82.7% vs. 68.4%
in WHO stage III/IV), higher prevalence of TB (16.2% vs.
10.0%), and HCV infection (52.6% vs. 18.1%).
Retention
Table S2 describes death, lost-to-follow-up, transfer out and
retention rates of patients after 6, 12, 24, 36 and 48 months.
Retention at 6 and 12 months was high for all patients (88.4% and
84.0%, respectively) as well as for PWID (86.7% and 81.5%) and
patients who did not report IDU (92.6% and 90.1%). However, by
24, 36 and 48 month, retention among non-IDU was significantly
better.
Factors associated with attrition are described in Table S3 with
crude and adjusted hazard ratios (AHR) and 95%CI. Male sex
(AHR 1.59, 95%CI: 1.26–1.99), history of IDU (AHR 1.58,
95%CI: 1.25–2.01), late presentation at WHO stage IV (AHR
1.48, 95%CI: 1.22–1.81), lower CD4 cell count (AHR 1.61,
95%CI: 1.28–1.93 for CD4 cell count between 50 and 200 cells/
mm3; AHR 2.40, 95%CI: 1.90–3.04 for CD4 below 50 cells/mm3)
and lower BMI (AHR 1.75, 95%CI: 1.51–2.03) were associated
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with attrition in the adjusted model. Having active TB at ART
initiation and having lower hemoglobin were associated with
attrition in the unadjusted analysis, not in the adjusted hazard
model. Similar factors (male, low CD4 cell count, late stage, low
BMI) were found associated with attrition for the PWID sub-
population. Site factors, including clinic type (provincial vs.
district), clinic location (rural vs. urban), and clinic size (i.e.,
number of patients) were also tested, and none of them showed
significant association with attrition. However, data related to the
MMT program was not available for analysis.
A Kaplan-Meier plot constructed to compare retention rates
between IDUs and non-IDUs (Figure S1) showed that patients
with a history of IDU had lower retention rates than patients
without it.
Immune Reconstitution Under ART
Median CD4 cell count gains were 94 cells/mm3 after 6
months, 142 cells/mm3 after 12 months, 213 cells/mm3 after 24
months, 254 cells/mm3 after 36 months, and 264 cells/mm3 after
48 months of ART (Table S2). The gain was rapid in the first 24
months and slower in the 3rd year of ART. Patients of both sexes
and patients with or without a history of IDU experienced
increases in CD4 cell count. However, patients with an IDU
history generally had poorer immune reconstitution than patients
without a history of IDU.
Discussion
We described cohorts of Vietnamese HIV-infected patients with
late presentation to care. Most patients registered at OPCs already
with advanced stages of HIV infection. These findings were similar
to reports from other resource-limited settings, including sub-
Saharan Africa [11,12,13,14,15,16,17,18], China [19], India [20],
Thailand [21] and Haiti [22]. Even after several years of
experience managing the national ART program, late presenta-
tion remains problematic in Vietnam as it does in many other
countries [12,20]. Although Vietnam’s ART program scaled up
rapidly from 2005 to 2009, the median CD4 cell count at clinic
registration and before ART remained under 100 cells/mm3
throughout this period. Significant stigma and discrimination
towards HIV-infected persons, weak Information/Education/
Communication programs and poor linkage between counseling
and testing services and OPCs may be factors contributing to late
access to care. Moreover, the scale-up rate in the early stage of the
ART program (i.e., 2004–2006) was slow due to time and
resources needed to set up OPCs, train health care workers, and to
gain experience for more rapid ART initiation and wider
coverage.
Although patients in this cohort presented with advanced
infections, 12-month retention on treatment was high (.80%).
Such retention is similar to those reported from a systematic
review of cohorts in sub-Saharan Africa [23], as well as country
specific reports from Rwanda [14] and South Africa, Malawi and
Côte d’Ivoire [15]. The national ARV program in Thailand also
achieved a high survival rate of 0.89 after 1 year and 0.78 after 5
years [21]. Moreover, despite low CD4 cell counts at baseline, our
evaluation showed a positive immunologic response to ART. The
gain in CD4 cell count continued steadily through the course of
ART, with a median gain of 94 cells/mm3 at six months and 142
cells/mm3 at 12 months. The trend continued at 24, 36, and 48
months. This promising response was similar to results found in
sub-Saharan Africa [11,12,14,17], China [19], Thailand [21], and
Haiti [22].
This programmatic evaluation also identified factors associated
with attrition. Being male, having a history of IDU, low CD4 cell
count, high WHO stage, and low BMI were risk factors for
attrition. Some of those, such as being male, low CD4 cell count,
high WHO stage, and low BMI were common risk factors
reported in resource-limited settings [11,14,17]. History of IDU
was a strong risk factor for attrition, which could be explained by
poor adherence, active drug use, or co-morbidities. Clinic factors
(i.e., size, type, location) were not found to be associated with
attrition, although factors specific to PWID (e.g., access to MMT)
were not available for analysis because the MMT program was still
being piloted at the time of the study.
The important difference between this study and other ART
cohorts is the high proportion of PWID. IDU has been the major
route of transmission in Vietnam [24]. PWID in this evaluation
presented with more advanced HIV infections and were more
likely to have evidence of HCV co-infection. Cohorts of PWID in
other countries have reported similar findings: PWID were more
likely to have lower nadir CD4 cell count measurements, present
with AIDS defining illnesses [25,26,27], have higher rates of active
TB [28], have higher prevalence of hepatitis/HIV co-infections
[29,30], and receive HIV diagnosis late [31]. In Vietnam, major
barriers for PWID to access care and treatment include poor
socioeconomic status, discrimination (and in some cases, self-
discrimination), lack of knowledge about HIV disease and benefits
of early testing and care, concern about confidentiality, lack of
transportation, limited availability of IDU-centered services such
as MMT and outreach support (Family Health International 360,
unpublished data).
Although retention of PWID at 12 months was also promising
(81.5%), fewer PWID than non-PWID were retained over the
course of ART: while non-PWID maintained retention rates of
88.2% at 3 years and 85.7% at 5 years, the retention rates of
persons with a history of IDU were significantly lower, only 67.4%
at three years and 63.3% at five years. Additionally, PWID were
found to have less robust immune reconstitution than patients
without a history of IDU (Table S2). Other reports have shown
that persons with a history of IDUs were less likely to achieve viral
load suppression [26], more likely to have treatment interruption,
[32] and lower CD4 gain [33]. In our evaluation, contributing
factors to less favorable outcomes of PWID might include ongoing
drug use, co-morbidities or poor adherence, although data were
not available to identify any associations. Because adherence data
were inconsistently recorded in the charts, we were not able to
analyze adherence among PWID. Anecdotal reports from clinics
participating in the evaluation showed that ongoing drug use
accounted for a number of patients who had died of presumed
overdose or had been confined to drug treatment centers without
continuing access to comprehensive care and ART. Efforts have
been made by VAAC to provide care to drug treatment center
residents and maintain ART access. Expansion of MMT and
other harm reduction programs targeting PWID with better
linkages to OPCs is underway and should help increase access to
care and improve adherence among PWID on ART.
The present evaluation had several limitations. First, data
quality was suboptimal because the source was patient charts used
by health care providers. Indeed, many data were missing,
including baseline CD4 cell count, weight, WHO stage, and viral
hepatitis sero-status. Testing was not always routinely performed
and therefore results were not always recorded. CD4 measurement
and viral hepatitis testing was not widely available at all clinics,
especially early in the ART program (i.e., 2004–2006). Another
important data quality issue was related to the adherence of
healthcare workers to national guidelines. Although Vietnamese
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national guidelines recommend WHO stage, weight, clinical
status, and adverse events to be recorded at every patient visit,
we found that a considerable number of charts were missing this
data (Table S1). ART laboratory monitoring was also often not
performed per guidelines, similar to another study [34]. Critical
tests such as CD4 cell count, liver transaminases, and hemoglobin
sometimes were not done at 6-month intervals as recommended.
Some patients did not have any CD4 measurements at follow up
or had CD4 measurements done more than 1 year after ART
initiation. These quality issues were reported back to VAAC to
help establish a more rigorous quality control program with the
goal of improving quality of care.
A second limitation was that we were not able to assess what
happened to patients who were lost to follow-up or to assess the
reasons for deaths as the charts did not routinely record these data.
Other studies tracking loss to follow-up reported that one third
[35,36] to half [37] of LTFU patients died and many of the
patients were untraceable. A meta-analysis of studies from Africa,
Asia and Latin America reported 40% of LTFU patients had died,
and among patients for whom re-contact was successful, reasons
for not returning to clinics included transfer to other programs,
financial difficulties, improving or decreasing health status and
stigma [38]. In the context of Vietnam, we would expect similar
circumstances. Many of the LTFU patients may have already
died. Especially in this population of PWID, active drug use may
contribute to loss to follow up, either because patients died or were
admitted to government drug treatment centers.
The third limitation was the ascertainment of IDU history.
Many patients who had used intravenous drugs may not have
revealed their history, leading to a falsely low proportion of PWID.
High HCV co-infection among reported non-PWID (18.1%) may
serve as a proxy for IDU status. Also, we were also not able to
obtain data on whether patients continued intravenous drug use
while on ART or whether they had access to MMT.
Despite these limitations, the evaluation provided significant
insights and useful lessons for the Vietnamese ART program. The
evaluation served as an assessment of data quality at OPCs and
based on its results recommendations were made to VAAC to 1)
revise the current patient chart format to be more user-friendly
and to capture additional important patient monitoring indicators;
2) provide training to OPC staff to increase data use for internal
quality improvement; 3) strengthen patient monitoring; 4)
emphasize the importance of routine quality control activities;
and 5) consider an evaluation of LTFU patients to better
understand their outcomes and reasons for LTFU. Although the
evaluation did not provide data to assess specific factors associated
with less desirable outcomes among PWID, such as ongoing drug
use, lack of access to MMT, and adherence, we believe that
strengthening IDU-specific interventions, such as linkage to MMT
which is becoming rapidly more available, as well as counseling
and treatment support, will help reduce LTFU and improve
treatment outcomes. In an effort to increase early access to ART,
VAAC revised the national guidelines in 2011 to raise the
threshold of CD4 cell count for ART initiation to 350 cells/mm3,
and it recommended ART to all patients with active TB regardless
of the counts. The Vietnam MOH also committed to piloting the
WHO/UNAIDS ‘‘Treatment 2.00 initiative [1]. Up to now, the
MMT program has been expanded to 41 clinics with stronger
linkages to OPCs. As a result of the combination of these efforts,
PWID may expect to experience more favorable outcomes.
Conclusion
Data from this routine program evaluation of ART scale-up in
Vietnam demonstrated a high retention rate and good immune
reconstitution in response to treatment, indicating a high level of
program quality in this predominately PWID population. How-
ever, efforts to promote earlier identification of HIV-infected
persons and earlier initiation of ART remain a priority, as well as
efforts to improve the quality of clinic services and data to further
reduce LTFU among PWID.
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